Bristol Myers Builds Pharma's Largest NVIDIA AI Supercomputer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Bristol Myers Squibb is assembling the largest AI supercomputer in the life sciences industry — the third pharma company to claim that title in nine months
- BMS launched its NVIDIA partnership three years ago with a smaller computing cluster focused on individual AI tools like protein structure prediction
- Greg Meyers, BMS's chief digital & technology officer, said the company "consumed all the space we had" on its existing cluster
- BMS is scaling up because it has become "more convinced" that foundation models can illuminate how drug candidates interact with the body and disease
- BMS has built foundation models in oncology and neurodegeneration, the therapeutic areas Meyers flagged as priorities for the new compute
Why it matters: BMS is the third pharma company in nine months to claim the industry's "largest" AI supercomputer, signaling an infrastructure arms race where compute scale is becoming a competitive moat. The bet is that foundation models trained on this hardware can compress early discovery timelines in oncology and neurodegeneration — therapeutic areas where BMS faces crowded pipelines.
